SCHEMBL25549133

SCHEMBL25549133

O=C(NC(C(=O)O)C(F)(F)F)c1ccc2cc(CO)ccc2c1OCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 1/20 0.49
▸ KIFC1 Q9BW19 1/20 0.38
▸ MME P08473 1/20 0.37
▸ ACE P12821 1/20 0.37
▸ CPA1 P15085 1/20 0.37
▸ ACE2 Q9BYF1 1/20 0.37
▸ PPARA Q07869 3/20 0.36
▸ PPARD Q03181 3/20 0.36
▸ PPARG P37231 2/20 0.36
▸ PTPN1 P18031 3/20 0.35
▸ PTPN2 P17706 2/20 0.35
▸ PTPN6 P29350 2/20 0.35
▸ AURKA O14965 1/20 0.35
▸ RPS6KB1 P23443 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ SENP5 Q96HI0 1/20 0.35
▸ SENP2 Q9HC62 1/20 0.35
▸ SENP1 Q9P0U3 1/20 0.35
▸ GPR132 Q9UNW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25555794 0.88 CXCR2 (0.49) CXCR2MMEACECPA1ACE2
SCHEMBL25549130 0.87 CXCR2 (0.64) CXCR2KIFC1MMEACECPA1
SCHEMBL25548972 0.87 CXCR2 (0.49) CXCR2MMEACECPA1ACE2
SCHEMBL25548796 0.86 CXCR2 (0.51) CXCR2KIFC1MMEACECPA1
SCHEMBL25548797 0.84 CXCR2 (0.54) CXCR2KIFC1MMEACECPA1
SCHEMBL23460679 0.84 CXCR2 (0.51) CXCR2KIFC1MMEACECPA1
SCHEMBL38147084 0.84 CXCR2 (0.51) CXCR2KIFC1MMEACECPA1
SCHEMBL23460680 0.84 CXCR2 (0.51) CXCR2KIFC1MMEACECPA1
SCHEMBL25549076 0.84 CXCR2 (0.46) CXCR2MRGPRX4
SCHEMBL23460975 0.83 CXCR2 (0.50) CXCR2KIFC1MMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885KIFC1 4789/4885MME 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback